Screener
Altimmune ALT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Altimmune’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
FAQ
- What is Altimmune's EPS (diluted)?
- Altimmune (ALT) reported EPS (diluted) of -$0.18 in Q1 2026.
- How has Altimmune's EPS (diluted) changed year-over-year?
- Altimmune's EPS (diluted) increased by 30.8% year-over-year, from -$0.26 to -$0.18.
- What is the long-term trend for Altimmune's EPS (diluted)?
- Over 4 years (2021 to 2025), Altimmune's EPS (diluted) has grown at a -19.2% compound annual growth rate (CAGR), from -$2.35 to -$1.00.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Altimmune's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude